Boehringer Ingelheim Implements Titian’s Mosaic Software
News Sep 17, 2013
Titian Software has announced that Boehringer Ingelheim has implemented its Mosaic™ sample management software for the inventory management, sample tracking, and sample processing of New Biological Entities (NBE).
Now well-established as a leading provider of sample management software for small molecule compound libraries, Titian has evolved Mosaic into enterprise-wide management of biological samples, reagents and standards.
The new installation has Boehringer Ingelheim incorporating Mosaic into their protein purification, gene expression, biological lead engineering, and biological lead generation workflows within the NBE groups.
Titian CEO, Edmund Wilson said: “Drug discovery is now more challenging than ever, and so pharmaceutical, biotech and academic organizations are seeking to maximize the efficiencies of their laboratory processes. Knowing where a sample is, what its character make-up is, and what has been done to it and by whom, is an essential element in this efficiency. Mosaic’s success has been built on the premise of listening to the needs of customers in various organizations. Based on this we have developed Mosaic to cover biological applications in addition to our heartland of chemical sample management, for which we are recognized as the ‘go-to’ offering.”
Mr Wilson continued: “We are delighted to announce this project with Boehringer Ingelheim which reflects Mosaic’s success with the management of biological samples.”
Mosaic is a modular software suite, providing a range of flexible options for many different types and sizes of life science research organizations in industry and academia.
Cow Antibodies Yield Important Clues For Developing A Broadly Effective AIDS VaccineNews
The unexpected animal model is providing clues for important questions at a moment when new energy has infused HIV vaccine research.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018
EMBL Course: RNA Sequencing Library Preparation - How Low Can You Go?
Mar 19 - Mar 23, 2018
EMBL Course: Analysis and Integration of Transcriptome and Proteome Data
Mar 12 - Mar 16, 2018
EMBO | EMBL Symposium: Tissue Self-Organisation: Challenging the Systems
Mar 11 - Mar 14, 2018
EMBL Course: Bioinformatics Resources for Protein Biology
Mar 06 - Mar 08, 2018